BeneVir Granted Patent Protecting Lead Oncolytic Immunotherapy Stealth-1H and Other Platform Assets
April 25 2017 - 8:00AM
Business Wire
BeneVir Biopharm, Inc., a biotechnology company developing
oncolytic immunotherapies for the treatment of cancer, announced
today that the U.S. Patent and Trademark Office has issued US
Patent No. 9,623,059, entitled “Oncolytic Herpes Simplex Virus and
Therapeutic Uses Thereof”, covering the composition of matter for
Stealth-1H, BeneVir’s lead oncolytic immunotherapy, as well as
other platform assets. BeneVir is a portfolio company within
Pansend Life Sciences, a subsidiary of HC2 Holdings, Inc. (NYSE
MKT: HCHC)
Oncolytic immunotherapies are live, infectious viruses that
selectively replicate in tumors with the goal of stimulating an
anti-tumor immune response. Stealth-1H is the first oncolytic
immunotherapy resistant to the anti-viral effects of both innate
and acquired immunity. This resistance allows Stealth-1H to safely
replicate, spread, and kill tumor cells despite a robust,
multi-armed immune attack against the virus. While anti-viral
immune attack is amplified when oncolytic immunotherapies are
combined with immunostimulatory agents such as anti-PD1/PDL1,
OX40L, and ICOS-Ligand, Stealth-1H hides from the immune system,
enabling maximum efficacy in combination with these agents.
The patent is exclusively licensed to BeneVir from NYU School of
Medicine. The technology originated in the lab of Ian Mohr, Ph.D.,
Professor of Microbiology at NYU School of Medicine, and Chair of
BeneVir’s Scientific Advisory Board. Dr. Mohr is a world leader in
the field of oncolytic immunotherapy and invented key intellectual
property used to create the first FDA-approved oncolytic
immunotherapy.
“I am delighted that this patent further strengthens the product
development program at BeneVir. I look forward to continuing the
exciting, productive relationship between BeneVir and my lab,” said
Dr. Mohr.
“This patent protects BeneVir’s product platform through 2032,”
said Matt Mulvey, BeneVir CEO. “We plan to bring Stealth-1H into
the clinic next year and accelerate the pre-clinical development of
our platform assets to help a diverse array of patients whose
tumors do not respond to current therapeutic options, including
immune checkpoint inhibitors.”
About BeneVir
BeneVir Biopharm, Inc., is a portfolio company within Pansend
Life Sciences, a subsidiary of HC2 Holdings, Inc. Its offices and
laboratories are located in Gaithersburg, MD, which is part of the
BioHealth Capital Region. BeneVir is developing a platform of
oncolytic immunotherapies based on T-StealthTM Technology, which
promotes the persistence and efficacy of oncolytic immunotherapies
in advanced tumors. Learn more about BeneVir at
http://www.benevir.com.
About HC2
HC2 Holdings, Inc. is a publicly traded (NYSE MKT:HCHC)
diversified holding company, which seeks opportunities to acquire
and grow businesses that can generate long-term sustainable free
cash flow and attractive returns in order to maximize value for all
stakeholders. HC2 has a diverse array of operating subsidiaries
across seven reportable segments, including Construction (formerly
Manufacturing), Marine Services, Energy (formerly Utilities),
Telecommunications, Life Sciences, Insurance and Other. HC2's
largest operating subsidiaries include DBM Global Inc., a
family of companies providing fully integrated structural and steel
construction services, and Global Marine Systems Limited, a
leading provider of engineering and underwater services on
submarine cables. Founded in 1994, HC2 is headquartered in New
York, New York. Learn more about HC2 and its portfolio companies
at www.hc2.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170425005240/en/
BeneVir Biopharm, Inc.Katherine Sacksteder, 240-474-5280orHC2
Holdings, Inc.Andrew Backman, 212-339-5836
HC2 (NYSE:HCHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
HC2 (NYSE:HCHC)
Historical Stock Chart
From Apr 2023 to Apr 2024